Milestones
Onyx receives Fast Track designation for carfilzomib and immediately begins NDA filing process on a rolling basis by submitting the preclinical module
Onyx reports positive complete results from Phase 2b study of single-agent carfilzomib in patients with relapsed and refractory multiple myeloma
Onyx enters into an exclusive agreement valued in excess of $300 million with Ono Pharmaceutical, giving Ono the rights to develop and commercialize carfilzomib and ONX 0912 for all oncology indications in Japan
Phase 3 ASPIRE trial begins, evaluating carfilzomib in combination with lenalidomide (Revlimid) and low-dose dexamethasone in patients with relapsed multiple myeloma
ONX 0912, an oral proteasome inhibitor, enters clinical testing
Onyx acquires Proteolix Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of patients with cancer and autoimmune diseases
Phase 3 DECISION trial begins, evaluating Nexavar in patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer
Onyx and Bayer report positive results from a Phase 2 trial evaluating Nexavar plus the chemotherapeutic agent, capecitabine, in patients with advanced breast cancer
Phase 3 MISSION trial begins, evaluating Nexavar in patients with NSCLC who have failed two or three previous treatments
Phase 2 SPACE trial begins, evaluating Nexavar in combination with TACE
Phase 3 SEARCH trial begins, evaluating Nexavar in combination with Tarceva
Hollings Renton retires as chairman and CEO of Onyx
N. Anthony Coles, M.D., joins Onyx as president and CEO
Nexavar pivotal liver cancer study (SHARP) published in The New England Journal of Medicine
Onyx acquires license to ONX 0801, a novel targeted oncology compound in preclinical development
Nexavar pivotal kidney cancer study (TARGET) published in The New England Journal of Medicine
Nexavar is approved as the first and only targeted therapy for the treatment of patients with unresectable liver cancer
Nexavar is approved for the treatment of patients with advanced kidney cancer; the first new drug in more than a decade to treat this disease, representing a breakthrough in the treatment of kidney cancer
PD 0332991, an oral, cell cycle inhibitor, enters clinical testing
Onyx focuses its efforts solely on the development of sorafenib and discontinues therapeutic virus program
Sorafenib (now Nexavar), an oral targeted therapy, enters clinical testing
Onyx and Warner Lambert, now Pfizer, extend collaboration in area of cell cycle regulation
Frank McCormick leaves Onyx to become head of the University of California, San Francisco Cancer Center and Cancer Research Institute
Onyx completes IPO and is listed on the Nasdaq under stock symbol ONXX
Onyx and Warner Lambert, now Pfizer, form collaboration to develop therapeutics for cell cycle regulation
Onyx and Miles Inc. (predecessor to Bayer HealthCare Pharmaceuticals, Inc.) form collaboration
Onyx appoints Hollings Renton as the company’s first president and CEO
Onyx Pharmaceuticals is founded by Frank McCormick to discover and develop cancer therapeutics and is spun out of the Cetus and Chiron merger as privately held company
Cetus Corporation merges with Chiron Corporation
Frank McCormick, Ph.D., begins cancer research program at Cetus Corporation
Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011
- SymbolONXX
- Last43.71 +0.22
- Open43.46
- High43.81
- Low42.49
- Volume1139204
Latest News
-
05/19/2011
-
05/18/2011
-
05/18/2011
-
05/18/2011
-
05/19/2011
-
05/18/2011
-
05/18/2011
-
05/18/2011
-
05/6/2021
-
05/4/2021
-
04/28/2011
-
04/21/2011
-
03/28/2011
-
03/11/2021
-
03/2/2022
-
02/24/2011
-
02/23/2011
-
02/15/2011
-
02/3/2021
-
01/31/2011
-
01/4/2021
-
12/7/2021
-
12/6/2021
-
11/18/2010
-
11/10/2021
-
11/9/2021
-
11/4/2021
-
11/3/2021
-
10/26/2010
-
10/7/2021
-
10/7/2021
-
10/7/2021
-
09/16/2010
-
09/8/2021
-
09/7/2021
-
08/4/2021
-
08/3/2021
-
07/28/2010
-
07/26/2010
-
07/23/2010
-
07/21/2010
-
06/14/2010
-
06/14/2010
-
06/8/2021
-
06/8/2021
-
06/5/2021
-
06/4/2021
-
06/1/2022
-
05/21/2010
-
05/20/2010
-
05/11/2021
-
05/5/2021
-
05/4/2021
-
05/4/2021
-
04/27/2010
-
03/16/2010
-
03/1/2022
-
02/23/2010
-
02/16/2010
-
02/2/2022
-
02/2/2022
-
02/1/2022
-
01/5/2021
-
12/11/2021
-
12/10/2021
-
12/7/2021
-
12/7/2021
-
12/6/2021
-
12/4/2021
-
11/25/2009
-
11/16/2009
-
11/11/2021
-
11/10/2021
-
11/4/2021
-
11/3/2021
-
10/29/2009
-
10/27/2009
-
10/23/2009
-
10/12/2021
-
10/12/2021
-
10/11/2021
-
09/30/2009
-
09/28/2009
-
09/24/2009
-
09/23/2009
-
09/15/2009
-
09/4/2021
-
09/2/2022
-
08/6/2021
-
08/6/2021
-
08/4/2021
-
08/4/2021
-
07/29/2009
-
07/22/2009
-
06/2/2022
-
06/1/2022
-
05/28/2009
-
05/20/2009
-
05/17/2009
-
05/14/2009
-
05/12/2021
-
05/6/2021
-
05/5/2021
-
04/28/2009
-
04/26/2009
-
04/26/2009
-
03/10/2021
-
03/3/2021
-
02/23/2009
-
02/12/2021
-
01/6/2021
-
01/5/2021
-
12/23/2008
-
11/6/2021
-
11/6/2021
-
11/5/2021
-
10/31/2008
-
10/29/2008
-
09/18/2008
-
08/21/2008
-
08/15/2008
-
08/5/2021
-
07/31/2008
-
07/30/2008
-
07/28/2008
-
07/23/2008
-
06/19/2008
-
06/4/2021
-
06/2/2022
-
05/16/2008
-
05/16/2008
-
05/8/2021
-
05/6/2021
-
05/5/2021
-
04/29/2008
-
04/24/2008
-
03/11/2021
-
03/11/2021
-
02/26/2008
-
02/19/2008
-
02/19/2008
-
02/18/2008
-
02/18/2008
-
02/6/2021
-
01/25/2008
-
01/2/2022
-
11/19/2007
-
11/6/2021
-
10/30/2007
-
10/25/2007
-
10/4/2021
-
10/3/2021
-
09/21/2007
-
09/18/2007
-
08/27/2007
-
08/20/2007
-
08/7/2021
-
07/31/2007
-
06/27/2007
-
06/21/2007
-
06/19/2007
-
06/18/2007
-
06/4/2021
-
05/25/2007
-
05/23/2007
-
05/9/2021
-
05/2/2022
-
04/27/2007
-
03/15/2007
-
03/8/2021
-
02/15/2007
-
02/12/2021
-
02/12/2021
-
02/9/2021
-
02/8/2021
-
02/1/2022
-
01/24/2007
-
01/10/2021
-
01/2/2022
-
12/4/2021
-
12/4/2021
-
11/7/2021
-
11/1/2022
-
10/12/2021
-
09/29/2006
-
08/8/2021
-
08/1/2022
-
07/24/2006
-
07/20/2006
-
06/13/2006
-
06/12/2021
-
06/6/2021
-
06/5/2021
-
06/1/2022
-
05/25/2006
-
05/10/2021
-
05/4/2021
-
05/3/2021
-
04/28/2006
-
04/27/2006
-
04/27/2006
-
04/26/2006
-
04/18/2006
-
03/30/2006
-
03/24/2006
-
03/2/2022
-
02/16/2006
-
02/16/2006
-
02/9/2021
-
02/8/2021
-
01/31/2006
-
01/5/2021